U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023731) titled 'A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation' on June 09.
Brief Summary: This is a study to evaluate the safety and potential anti-tumor activity of an investigational agent called ARV-806 in Adults with Advanced Cancer having a specific KRAS mutation. This is an open-label study which means that participants and study staff will know that all participants will receive ARV-806.
Researchers think that ARV-806 can work by breaking down a specific protein with a mutation that is present in some tumors, which might help prevent or slow tumors from growing. This will be the first time ARV-80...